News and Reports
-
Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals
15 March 2021Download -
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
12 March 2021Download -
Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
12 March 2021Download -
NEURELIS ANNOUNCES CLOSE OF $114 MILLION SERIES D FINANCING ROUND TO ADVANCE NEUROSCIENCE FOCUS
10 March 2021Download -
eGenesis Announces $125 Million Series C Financing
2 March 2021Download -
SWIXX SIGNS CEE REGIONAL AGREEMENT WITH SEAGEN FOR TUKYSA®
1 March 2021Download -
NovellusDx Establishes Fore Biotherapeutics and Appoints Dieter Weinand as Chairman of the Board and Usama Malik as Chief Executive Officer and Director of the Board
22 February 2021Download -
Swixx BioPharma SA of Baar, Switzerland announced today that it had signed eighteen deals for new territories and / or products over the past year
5 February 2021Download -
Horizon Therapeutics to acquire HBM portfolio company Viela Bio for USD 3.05 billion in cash
1 February 2021Download -
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis
1 February 2021Download -
Narrow River Management Announces Formation and Financing of Two New Companies Developing Therapies for Renal Diseases
27 January 2021Download -
Farmalatam Holding Inc. (Farmalisto) achieves investment of US $ 18 million from the IDB Invest, HBM Healthcare Investments Ltd. and Morgan Río Capital Management
15 January 2021Download -
IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncologypdf.
13 January 2021Download -
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
11 January 2021Download -
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
9 January 2021Download -
Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO
4 January 2021Download -
Y-MABS Therapeutics and Swixx Complete CEE & RUSSIA Deal on DANYELZA® and OMBURTAMAB
18 December 2020Download -
BioAtla Announces Pricing of Initial Public Offering
15 December 2020Download -
Nuance Pharma Closes Series D Financing
8 December 2020Download -
Seer Announces Pricing of Initial Public Offering
4 December 2020Download -
Adrenomed Closes EUR 22 Million Equity Financing to Accelerate Development of Adrecizumab (HAM8101) and Provides Business Update
30 November 2020Download -
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
25 November 2020Download -
Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis
23 November 2020Download -
Enhancing Market Position in the Synthetic Biology Industry to Promote High End Biologically Manufactured Alternatives?A Dialogue with Cathay Biotech Inc. Chairman Liu Xiucai
20 November 2020Download -
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
16 November 2020Download